Quibim Competitive Intelligence & Landscape

Quibim (quibim.com) is a leading healthtech company that leverages AI for Medical Imaging, specializing in radiomics and biomarkers to transform imaging data into actionable predictions [https://quibim.com/]. Founded commercially in 2021 after years of intensive research, the company is headquartered in Valencia, Spain, with a presence in New York, USA [https://quibim.com/newsroom/news-and-press-releases/quibim-announces-50-million-in-series-a-financing/, https://quibim.com/news/understanding-quibim-corporate-governance/]. Their core mission is to design pioneering tools that unlock imaging data, ultimately improving patient outcomes through AI-guided precision solutions [https://quibim.com/about/].

Quibim offers a cloud-based, tissue-agnostic platform capable of extracting key radiomics drivers from large imaging data registries. Their flagship product, QP-Insights®, is a comprehensive platform that handles, indexes, stores, and harmonizes imaging data, minimizing variability and linking it with EHR information and multi-omics techniques [https://quibim.com/]. The company also develops a portfolio of cutting-edge clinical tools, including regulatory cleared medical devices such as QP-Prostate®, which streamlines prostate MRI reads with AI, providing precise quantitative information and automating tasks [https://quibim.com/products/, https://quibim.com/].

The company’s target market includes healthcare providers, biopharma companies, real-world evidence-driven teams, research institutions, and hospitals, whom they partner with to accelerate drug development programs, identify candidates for clinical studies, and monitor treatment responses [https://quibim.com/, https://quibim.com/trust-hub/].

Quibim is committed to data security, being ISO 27001:2022 certified and compliant with HIPAA and GDPR for data processing and storage on Microsoft Azure’s cloud platform [https://quibim.com/]. They closed a $50 million Series A financing round in early 2025, reflecting significant growth and impact in precision medicine [https://quibim.com/newsroom/news-and-press-releases/quibim-announces-50-million-in-series-a-financing/].

Quibim (quibim.com) specializes in transforming medical imaging data into actionable predictions through advanced AI and radiomics. The company offers a cloud-based, tissue-agnostic platform designed to extract critical radiomics drivers from extensive imaging data registries. Their core offerings include the Quibim Platform, which emphasizes data security with ISO 27001:2022 certification and compliance with HIPAA and GDPR, utilizing Microsoft Azure for secure and unlimited data storage. A key product within this platform is QP-Insights®, a comprehensive solution for managing, indexing, storing, and harmonizing imaging data, linking it with EHR information and other multi-omics techniques. While the website highlights the capabilities and products, specific pricing plans, tiers, or details on free versus paid features are not explicitly stated on the provided homepage content.

Quibim also develops best-in-class Software as a Medical Device for healthcare providers, demonstrating their commitment to practical clinical applications. Notable products include QP-Prostate®, an AI solution designed to integrate seamlessly with PACS systems, aiming to revolutionize prostate MRI reads by providing precise, quantitative information and automating tasks for radiologists. Other specialized products include QP-Brain®, QP-Liver®, QP-Breast®, and QP-Lung®, indicating a broad application across various medical imaging domains. The information provided, however, does not detail any specific pricing models for these individual products or the platform as a whole.

In addition to their platform and products, Quibim engages in Life Sciences partnerships with biopharma companies. They leverage their AI models to accelerate drug development programs, helping identify candidates for clinical studies, predicting patient responses to drugs, and monitoring toxicity and adverse events. The content showcases their work through case studies and research, such as predicting survival in B-Cell lymphoma patients or empowering neuroblastoma risk stratification. Despite the clear value proposition in both clinical and research settings, the provided text does not offer insights into the pricing structure, subscription models, or any recent changes to their pricing strategy for either their life sciences partnerships or their commercial products.

Quibim actively seeks to expand its global team, focusing on individuals passionate about transforming precision health through AI for medical imaging [quibim.com/about/careers/]. The company emphasizes a culture of innovation, courage, trust, and integrity, valuing proactive communication and transparent collaboration among its diverse workforce [quibim.com/about/culture-values/]. This commitment to a positive work environment is underscored by its Great Place to Work® certification with a score of 93/100, achieved by the Valencia-founded company, which further expanded to five international offices in Europe and the United States in 2022 [quibim.com/newsroom/news-and-press-releases/quibim-obtains-the-great-place-to-work-certification-with-a-score-of-93-100/].

Recent strategic hires at Quibim indicate a clear focus on accelerating global growth and strengthening life sciences partnerships. The company notably appointed Itta MacNevin as Chief Business Officer to drive global expansion and foster collaborations within the life sciences sector [quibim.com/news-press-releases/]. Furthermore, Jeanne Bolger was brought on as an independent director and advisor specifically to accelerate growth in the life sciences domain [quibim.com/news-press-releases/]. These appointments signal a robust strategy to deepen its engagement with biopharma companies and leverage its AI imaging biomarker technology for drug development programs.

The consistent emphasis on careers related to AI imaging, radiomics, and biomarkers reflects Quibim's core mission to unlock imaging data for improved patient outcomes [quibim.com]. The company's hiring patterns demonstrate a strategic push for talent that can contribute to its cloud-based, tissue-agnostic platform, which extracts key radiomics drivers from extensive imaging data registries. This strategic hiring aligns with Quibim's ambition to transform healthcare through AI-guided precision solutions and its expansion into new international markets [quibim.com/about/].

Quibim, a leader in AI for medical imaging, secured $50 million in Series A financing led by Asabys and Buenavista. This substantial investment is earmarked for expanding Quibim's product pipeline, developing foundational AI models, and accelerating its global commercial growth. The funding underscores the company's commitment to revolutionizing precision medicine through its advanced imaging biomarker solutions [https://quibim.com/newsroom/news-and-press-releases/quibim-announces-50-million-in-series-a-financing/].

Beyond private funding, Quibim has also been successful in securing significant grants. The company was awarded €1,475,682.48 as part of the EUCAIM project, co-funded by the European Union under Grant Agreement number 1011100633. This project, originating from the expertise of the AI for Health Imaging Network (AI4HI), focuses on big data and AI in cancer imaging, involving numerous institutions across 20 countries. Additionally, Quibim received another grant amounting to €458.75 [https://quibim.com/grants/].

In terms of strategic growth and executive appointments, Quibim appointed Itta MacNevin as Chief Business Officer (CBO) in April 2026. This appointment is a key component of Quibim's strategy to accelerate its global expansion and strengthen its partnerships within the life sciences sector, indicating a clear focus on increasing market presence and fostering collaborations [https://quibim.com/newsroom/news-and-press-releases/quibim-appoints-itta-macnevin-as-chief-business-officer-to-accelerate-global-growth-and-life-sciences-partnerships/].

Quibim actively participates in and hosts numerous events to showcase its advancements in AI for medical imaging and to engage with the global healthcare community. The company is a consistent presence at major international radiology congresses. For instance, Quibim is set to present its latest innovations at the European Congress of Radiology (ECR) in 2025, following its participation in ECR 2024 in Vienna, where it highlighted the vanguard of medical imaging and AI. Similarly, Quibim will attend the Radiological Society of North America (RSNA) annual meeting in 2025 in Chicago, building on its participation in RSNA 2024 to explore new frontiers in medical imaging and precision medicine through AI-powered biomarkers.

Beyond radiology-focused events, Quibim also engages with the oncology community. The company will present four oncology imaging publications at the American Society of Clinical Oncology (ASCO) annual meeting in 2025. This follows their participation in ASCO 2024 in Chicago, where they explored the convergence of art and science in cancer care and the possibilities of medical imaging applied to oncology.

Quibim also extends its educational outreach through webinars and collaborations. The company partnered with SERAM (Sociedad Española de Radiología Médica) for a webinar in 2025 focused on clinical cases in prostate cancer, following a similar joint webinar in 2024 that discussed real clinical cases with leading radiologists. Additionally, Quibim hosted a webinar on "Biomarker Imaging Analysis and Real Time Clinical Trial Capabilities," demonstrating its commitment to knowledge sharing and fostering discussions on cutting-edge topics in medical imaging.